Immune response of infants and children to low-passage bovine rotavirus (strain WC3).
A bovine rotavirus (strain WC3) was isolated from a calf in Pennsylvania and adapted to growth in continuous Cercopithecus cell line CV1. A pool for human vaccine trials was produced at the 12th cell culture passage level. After preliminary testing in adults and older children, a dose of 3 X 10(7) plaque-forming units was given by mouth to 52 infants and children aged 5 months to 6 years. No clinical sequelae were detected, and shedding in feces was detected in only 30% of tested infants. A serum-neutralizing antibody response was induced in 95% of 21 infants aged 5 to 11 months; response rates were slightly reduced in older infants. The antibody response was primarily directed toward bovine rotavirus, but a response to human serotype 3 rotavirus was also observed in approximately 50% of vaccinees. After vaccination with WC3, infants with preexisting antibody to rotaviruses of human serotype 1 or 3 frequently exhibited a booster response to those serotypes. WC3 is a candidate rotaviral vaccine deserving larger trials in children.
D000328:Adult; D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis / Q000096:biosynthesis* / Q000502:physiology; D000918:Antibody Specificity; D002417:Cattle; D002648:Child; D002675:Child, Preschool; D005243:Feces / Q000382:microbiology; D005744:Gastric Acid / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007223:Infant; D012401:Rotavirus / Q000145:classification / Q000276:immunology* / Q000302:isolation & purification; D012400:Rotavirus Infections / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control; D022243:Rotavirus Vaccines; D012703:Serotyping; D014765:Viral Vaccines / Q000494:pharmacology*
D000914:Antibodies, Viral; D022243:Rotavirus Vaccines; D014765:Viral Vaccines; C058442:WC3 rotavirus vaccine